NO892303L - Stabilisert fgf-sammensetning og fremstilling derav. - Google Patents

Stabilisert fgf-sammensetning og fremstilling derav.

Info

Publication number
NO892303L
NO892303L NO89892303A NO892303A NO892303L NO 892303 L NO892303 L NO 892303L NO 89892303 A NO89892303 A NO 89892303A NO 892303 A NO892303 A NO 892303A NO 892303 L NO892303 L NO 892303L
Authority
NO
Norway
Prior art keywords
mutein
fgf
sulfate
glucan
amino acid
Prior art date
Application number
NO89892303A
Other languages
English (en)
Norwegian (no)
Other versions
NO892303D0 (no
Inventor
Koichi Kato
Kenji Kawahara
Tomoko Kajio
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO892303D0 publication Critical patent/NO892303D0/no
Publication of NO892303L publication Critical patent/NO892303L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO89892303A 1988-06-06 1989-06-05 Stabilisert fgf-sammensetning og fremstilling derav. NO892303L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13890788 1988-06-06
JP18577288 1988-07-25

Publications (2)

Publication Number Publication Date
NO892303D0 NO892303D0 (no) 1989-06-05
NO892303L true NO892303L (no) 1989-12-07

Family

ID=26471846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89892303A NO892303L (no) 1988-06-06 1989-06-05 Stabilisert fgf-sammensetning og fremstilling derav.

Country Status (14)

Country Link
US (1) US5314872A (de)
EP (1) EP0345660B1 (de)
JP (1) JP2929200B2 (de)
KR (1) KR910001044A (de)
CN (1) CN1038765A (de)
AT (1) ATE79762T1 (de)
AU (1) AU614137B2 (de)
CA (1) CA1329763C (de)
DE (1) DE68902583T2 (de)
DK (1) DK246589A (de)
FI (1) FI892727L (de)
HU (1) HU205144B (de)
IL (1) IL90348A0 (de)
NO (1) NO892303L (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9102107D0 (en) * 1991-01-31 1991-03-13 Erba Carlo Spa Stabilisation of fibroblast growth factor using a polysaccharide
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
JPH0771459B2 (ja) * 1991-05-15 1995-08-02 三協食品工業株式会社 機能性食品素材とその製造方法
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
CA2124857A1 (en) * 1991-11-11 1993-05-27 Howard C. Herrmann Methods of inhibiting restenosis
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
AU659723B2 (en) * 1992-02-14 1995-05-25 Kaken Pharmaceutical Co., Ltd. Remedy for airway diseases
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JPH11130636A (ja) * 1997-10-28 1999-05-18 Noevir Co Ltd 毛髪用化粧料
CA2329010A1 (en) * 1998-04-17 1999-10-28 Angiogenix Incorporated Therapeutic angiogenic factors and methods for their use
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) * 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
JP5704780B2 (ja) * 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
EP2310039B1 (de) * 2008-05-02 2014-07-16 University Of Western Ontario Fgf-9 und seine anwendung in verbindung mit blutgefässen
FR2948286B1 (fr) 2009-07-27 2011-08-26 Jean-Noel Thorel Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes
FR2954165B1 (fr) * 2009-12-18 2012-01-13 Jean-Noel Thorel Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
WO2013147264A1 (ja) 2012-03-30 2013-10-03 味の素株式会社 硫酸化化合物を含む幹細胞増殖用培地
CN105288591A (zh) * 2015-10-29 2016-02-03 段懿玲 碱性成纤维细胞生长因子组合物及其在制备治疗脊髓损伤的药物中的应用
PL3380508T3 (pl) 2015-11-27 2021-07-12 Masarykova Univerzita Termostabilny polipeptyd fgf2, jego zastosowanie
JP6741021B2 (ja) * 2015-12-15 2020-08-19 日立化成ダイアグノスティックス・システムズ株式会社 線維芽細胞増殖因子−２３の安定化剤
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
WO2018221544A1 (ja) * 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
JP7177696B2 (ja) * 2018-12-28 2022-11-24 日清ファルマ株式会社 生理活性ペプチド又は生理活性タンパク質の活性低下抑制剤
CN110151977B (zh) * 2019-05-29 2022-11-29 新乡医学院 一种保护aFGF蛋白药物稳定性和活性的方法
TWI865835B (zh) * 2020-11-16 2024-12-11 雅祥生技醫藥股份有限公司 穩定的酸性纖維母細胞生長因子組合物
EP4183796A1 (de) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostabiles fgf10-polypeptid oder fragment davon, verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution

Also Published As

Publication number Publication date
CA1329763C (en) 1994-05-24
CN1038765A (zh) 1990-01-17
US5314872A (en) 1994-05-24
FI892727A0 (fi) 1989-06-02
EP0345660B1 (de) 1992-08-26
KR910001044A (ko) 1991-01-30
AU3496989A (en) 1989-12-07
HU205144B (en) 1992-03-30
DE68902583T2 (de) 1993-01-21
JP2929200B2 (ja) 1999-08-03
IL90348A0 (en) 1989-12-15
DK246589A (da) 1989-12-07
FI892727A7 (fi) 1989-12-07
NO892303D0 (no) 1989-06-05
AU614137B2 (en) 1991-08-22
HUT52393A (en) 1990-07-28
EP0345660A1 (de) 1989-12-13
ATE79762T1 (de) 1992-09-15
DE68902583D1 (de) 1992-10-01
FI892727L (fi) 1989-12-07
DK246589D0 (da) 1989-05-22
JPH02138223A (ja) 1990-05-28

Similar Documents

Publication Publication Date Title
NO892303L (no) Stabilisert fgf-sammensetning og fremstilling derav.
US5951972A (en) Stabilization of somatotropins and other proteins by modification of cysteine residues
EP0281822B1 (de) Basic fibroblast growth factor mutein, DNS und deren Verwendung
EP0486862B1 (de) Chimeres Fibroblasten-Wachstumsfaktor
NO180379B (no) Fremgangsmåte for fremstilling av et vesentlig renset insulinderivat
JPH08506095A (ja) 改変インシュリン様成長因子
FI118385B (fi) Uusi menetelmä biologisesti aktiivisen proteiinin valmistamiseksi
JPH0240399A (ja) 線維芽細胞増殖因子ムテインの複合体あるいは組成物
US5223483A (en) Cysteine-modified acidic fibroblast growth factor
JPH08301899A (ja) Ｉｇｆ−１スーパーアゴニスト
HU206375B (en) Process for producing biologically active, stable somatotropins and pharmaceutical compositions comprising same as active ingredient
US5120715A (en) Method for purifying fibroblast growth factor protein
DK174961B1 (da) Fibroblast-vækstfaktor, nucleotidsekvens kodende derfor, præparat indeholdende faktoren og fremgangsmåde til fremstilling deraf
EP0326907A1 (de) Polypeptide, DNA und ihre Verwendung
KR20200078414A (ko) 인슐린 및 글루카곤을 포함하는 약학 조성물
DK173380B1 (da) Præparat med mitogenisk aktivitet over for menneskeforhuds-fibroblaster, fremgangsmåde til fremstilling af en human, basisk
US6531134B1 (en) Mammalian milk growth factor
EP0421455A1 (de) Mutein von HST-1 und seine Herstellung
WO2022250556A4 (en) Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
US5852177A (en) Basic fibroblast growth factor (bFGF) muteins
CA2115522A1 (en) Hst-2 mutein, dna coding for the same and preparation thereof
JP2832354B2 (ja) ムテイン，ｄｎａおよびその用途
JPH07126293A (ja) ｈｓｔ−２ムテイン、その製造法および用途
DK166730B (da) Humaninsulinanaloger og deres farmaceutisk tolerable salte samt farmaceutiske praeparater indeholdende disse
JPH03184998A (ja) ハイブリッド蛋白質，ｄｎａおよびその用途